Grace to expand pharma portfolio with Albemarle’s business acquisition
US-based company W R Grace is set to expand its pharma portfolio with the acquisition of Albemarle’ Fine Chemistry Services…
26 Feb 2021
Merck signs agreement to buy Pandion Therapeutics for $1.85bn
Merck has agreed to acquire biotechnology company Pandion Therapeutics for approximately $1.85bn to expand its portfolio of autoimmune disease-targeting candidates. Under the agreement, Merck will initiate a tender offer through…
22 Feb 2021
Humacyte agrees SPAC merger to go public with bioengineered tissue tech
Human tissue bioengineering biotech Humacyte has entered into a business combination agreement with special purpose acquisition company (SPAC) Alpha Healthcare Acquisition Corp (AHAC). The deal allows Humacyte to become a…
19 Feb 2021
Lilly, Rigel enter $960m deal to develop RIPK1 inhibitors
Eli Lilly and Company and Rigel Pharmaceuticals have entered into a global exclusive license agreement and strategic collaboration to co-develop and commercialise the latter’s receptor-interacting serine / threonine-protein kinase 1…
18 Feb 2021
GSK, Vir expand collaboration for influenza, respiratory virus therapies
GlaxoSmithKline (GSK) has signed a binding agreement with Vir Biotechnology to expand its existing partnership to research and develop novel therapies for influenza and other respiratory viruses. Last April, the…
12 Feb 2021
Molecular Templates and BMS partner for cancer therapies development
Molecular Templates (MTEM) has entered a collaboration with Bristol Myers Squibb (BMS) to discover and develop multiple novel therapies. These therapies will be designed for specific oncology targets. The worldwide…
12 Feb 2021
Sandoz signs $500m deal to acquire GSK’s cephalosporin antibiotics business
Novartis division Sandoz has signed a $500m agreement to acquire GSK's cephalosporin antibiotics business to strengthen its global position in antibiotics. The deal consists of the global rights to the…